Adaptive Biotechnologies Showcases ClonoSEQ at ASH Annual Meeting
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a leader in biotechnology, will be presenting its cutting-edge clonoSEQ test for measurable residual disease (MRD) assessment at the forthcoming 67th Annual Meeting of the American Society of Hematology (ASH). The meeting is scheduled to take place from December 6 to 9, showcasing significant advancements in blood cancer treatment.
Broad Spectrum of Abstracts Featuring clonoSEQ
This year, a remarkable 89 abstracts featuring clonoSEQ, including 36 oral presentations, will highlight its application across various blood cancers such as multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). This information underscores clonoSEQ's dominance as the most trusted next-generation sequencing-based MRD test available for hematologic malignancies.
Impact of clonoSEQ MRD on Clinical Practice
The data presented will include over 17 case studies demonstrating how clonoSEQ MRD assessments are significantly influencing real-world treatment strategies for patients, guiding therapeutic decisions in ALL, CLL, MM, MCL, and DLBCL. The real-world impact of these findings is immense, showcasing clonoSEQ’s potential in enhancing patient outcomes.
Enhancing Clinical Trial Efficacy
Moreover, Adaptive Biotechnologies is expanding the utility of clonoSEQ in clinical trials, allowing for an unprecedented level of analysis concerning treatment efficacy. This initiative paves the way for evaluating novel therapies including CAR T-cell treatments, bispecific antibodies, and other targeted strategies in diverse blood cancer treatments, reinforcing clonoSEQ’s crucial role in advancing modern oncology practices.
Quote from Adaptive Executive
“It’s inspiring to see the vast number of ASH presentations utilizing clonoSEQ this year, confirming the essential place MRD testing holds in patient management and clinical investigation within hematologic oncology,” shared Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies. “This growth reflects MRD’s multifaceted contribution to contemporary lymphoid cancer care, from aiding treatment decisions to accelerating innovation.”
What is clonoSEQ?
clonoSEQ represents a significant advancement as the first and only FDA-cleared in vitro diagnostic (IVD) test certified for detecting and monitoring minimal (or measurable) residual disease (MRD) in patients with multiple myeloma or B-cell acute lymphoblastic leukemia, utilizing bone marrow samples. The test also extends its application to patients with chronic lymphocytic leukemia using blood or bone marrow and is additionally available in various other hematologic malignancies as a CLIA-validated laboratory developed test.
How clonoSEQ Works
What sets clonoSEQ apart is its capacity to identify and quantify DNA sequences within malignant cells with unmatched precision, detecting one cancer cell per million healthy cells. This capability empowers clinicians and researchers to consistently evaluate and monitor MRD status over time, ensuring effective communication of treatment statuses and aiding in predicting potential outcomes in cancer management.
About Adaptive Biotechnologies
Adaptive Biotechnologies is dedicated to utilizing the adaptive immune system's biology to transform the landscape of disease diagnosis and treatment. By unlocking the genetic potential of the immune system, Adaptive aims to enhance patient care globally. Their advancing technology ecosystem supports numerous initiatives, partnering with biopharmaceutical companies to facilitate innovative drug development pathways, especially in the realms of Minimal Residual Disease and Immune Medicine.
Frequently Asked Questions
What is clonoSEQ used for?
clonoSEQ is primarily used for detecting and monitoring measurable residual disease in patients with blood cancers, helping guide treatment decisions.
Where will clonoSEQ be showcased?
clonoSEQ will be prominently featured at the 67th Annual Meeting of the American Society of Hematology (ASH).
How many abstracts will feature clonoSEQ?
A total of 89 abstracts, including 36 oral presentations, will include research on clonoSEQ.
Who leads Adaptive Biotechnologies?
Adaptive Biotechnologies is led by a team of experienced professionals, including Susan Bobulsky, the Chief Commercial Officer.
Is clonoSEQ FDA approved?
Yes, clonoSEQ is the first and only FDA-cleared test for measurable residual disease assessment in specific blood cancers.
